Last reviewed · How we verify
CHF5993
CHF5993, marketed by Chiesi Farmaceutici S.p.A., is a small molecule with a specific biological mechanism targeting a primary indication. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CHF5993 |
|---|---|
| Also known as | TRIMBOW®, beclometasone dipropionate /formoterol fumarate/glycopyrronium bromide, BDP/FF/GB, BDP/FF/GB Placebo |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (PHASE3)
- Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (PHASE4)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (PHASE4)
- Functional Respiratory Imaging Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF5993 CI brief — competitive landscape report
- CHF5993 updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI